9

1-3
4==
-1
>==
O==c
O === .
~== va
- U
-

PTO/SB/05 (11-00) Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE d to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to re NEXSI-01011US0 UTILITY Attorney Docket No. PATENT APPLICATION Michael Freed First Inventor TRANSMITTAL Secure Sockets Layer Cut Through Architectus Express Mail Label No. EL 901895778 US (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or 1 1 mst an original and a duplicate for fee proce Computer Program (Appendix) Applicant claims small entity status. 2. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1 27 (if applicable, all necessary) [Total Pages 39 Specification 3 1 Computer Readable Form (CRF) - Descriptive title of the invention Specification Sequence Listing on: - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D i. CD-ROM or CD-R (2 copies); or - Reference to sequence listing, a table ii. paper or a computer program listing appendix Statements verifying identity of above copies - Background of the Invention Brief Summary of the Invention
 Brief Description of the Drawings (if filed) ACCOMPANYING APPLICATION PARTS - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3.73(b) Statement Power of 10 . Abstract of the Disclosure Attorney (when there is an assignee) English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets] Copies of IDS Information Disclosure 5. Oath or Declaration [Total Pages Statement (IDS)/PTO-1449 Citations Preliminary Amendment 13 Newly executed (original or copy)
Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) 14. (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) DELETION OF INVENTOR(S) 15 Signed statement attached deleting inventor(s) Request and Certification under 35 U.S.C. 122 named in the prior application, see 37 CFR 16 1.63(d)(2) and 1 33(b) (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet, See 37 CFR 1.76 Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Prvisional Continuation-in-part (CIP) of oper application No. Group Art Unit For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be reiled upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS 28554 Customer Number or Bar Code Labe. Larry E. Vierra, Esq. Name Vierra Magen Marcus Harmon & DeNiro, LLP 685 Market Street, Suite 540 Address San Francisco State California Zin Code 94105-4206 City (415) 369-9660 Country USA Telephone Fax (415) 369-9665 Registration No. (Attorney/Agent) 33,809 Larry E. Name (Print/Type) Date | July 6, 2001 Signature Burden Hour Statement This form is estimated to fasted 2 hours to complete Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete the form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, visitington, DC 2023.1 Do NOT SEXID PEES Sup-COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patients, Box Patient Application, 50.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC Washington, DC 20231

CHEROMONIC COMPONENTIAL PROPERTY CONTINUES IN CONTINUES I